China (Mainland)
Sirolimus / Rapamycin Derivative CAS 159351-69-6 Everolimus Powder CAS NO.159351-69-6
- FOB Price: USD: 150.00-200.00 /Kilogram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
Pharmaceutical Grade(1-10)KilogramPharmaceutical Grade(11-100)Kilogram
- Product Details
Keywords
- Everolimus
- 159351-69-6
- Everolimus Powder
Quick Details
- ProName: Sirolimus / Rapamycin Derivative CAS 1...
- CasNo: 159351-69-6
- Molecular Formula: C53H83NO14
- Appearance: White powder
- Application: 1. Adult patients with advanced renal ...
- DeliveryTime: Abiut 10 days
- PackAge: Aluminum foil bag,fluorinated bottles,...
- Port: Shenzhen port
- ProductionCapacity: 10 Metric Ton/Month
- Purity: 99%
- Storage: Store in cool & dry place. Keep away f...
- Transportation: 1) Door to Door Service by DHL/FEDEX/E...
- LimitNum: 1 Gram
- Moisture Content: <0.1%
- Impurity: <0.1%
Superiority
1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.
Details
|
Product Name |
Everolimus |
|
Synonyms |
42-O-(2-Hydroxyethyl)-rapamycin 42-O-(2-Hydroxy)ethylrapamycin |
|
CAS |
159351-69-6 |
|
Molecular Formula |
C53H83NO14 |
|
Molecular Weight |
958.232 |
|
Density |
1.18 |
|
Boiling Point |
998.7°C at 760 mmHg |
|
Flash Point |
557.8 °C |
|
Storage |
−20°C |
|
Refractive Index |
1.548 |
|
Appearance |
White powder |
|
Solubility |
Soluble in dimethysulfoxide,ethanol and chloroform. Slightly soluble in water. |
Description:
Everolimus is a derivative of Rapamycin(sirolimus), and works similarly to Rapamycin as an mTOR(mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors, Everolimus takes effect solely on the mTORC1 protein and not on the mTORC2 protein. In transplantation medicine, it is marketed under the trade names Zortress(USA) and Certican(Europe). It has been also used for the treatment of tumors, being marketed as Afinitor(general tumours) and Votubia(tumours as a result of TSC) in oncology.
Function:
Everolimus is indicated for the treatment of the following patients:
1. Adult patients with advanced renal cell carcinoma who have failed to receive either sunitinib or sorafenib.
2. Unresectable, locally advanced or metastatic, well-differentiated (moderately differentiated or highly differentiated) advanced pancreatic neuroendocrine tumors in adult patients.
3. Adult and pediatric patients with subsegmental giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TSC) requiring therapeutic intervention but not suitable for surgical resection. The effectiveness of this product is primarily demonstrated by sustainable objective relief (ie, the reduction in SEGA tumor volume). Patients with subsegmental giant cell astrocytoma associated with tuberous sclerosis have not been shown to have improved disease-related symptoms and prolonged overall survival.
FAQ
